<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308125</url>
  </required_header>
  <id_info>
    <org_study_id>CIP 2009-03 PREPARE PICSO</org_study_id>
    <nct_id>NCT01308125</nct_id>
  </id_info>
  <brief_title>Safety And Feasibility Study Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention</brief_title>
  <acronym>PICSO</acronym>
  <official_title>PREPARE PICSO A Study To Evaluate The Safety And Feasibility Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miracor Medical SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Miracor Medical SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pressure intermittent coronary sinus occlusion (PICSO) in patients with coronary artery&#xD;
      disease improves collateral flow index to higher than 30%. PICSO used in this patient&#xD;
      population is safe, feasible and effective. Safety, feasibility and effectiveness will be&#xD;
      tested by periprocedural and logistic data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1 Background Good collateral flow in case of obstructive coronary artery disease and acute&#xD;
      myocardial has beneficial effects on morbidity and mortality. Pressure controlled&#xD;
      Intermittent Coronary Sinus Occlusion (PICSO) carries a promise of improving myocardial flow,&#xD;
      decreasing microvascular obstruction and decreasing the rate of peri-procedural and acute&#xD;
      myocardial infarction without the increased risk of bleeding such as is encountered with&#xD;
      gp2b3a inhibitors. This study is designed to evaluate the safety and feasibility of PICSO in&#xD;
      patients with stable coronary artery disease and experimental short coronary artery&#xD;
      occlusion.&#xD;
&#xD;
      2. Objective The purpose of the study is to determine whether PICSO is safe and feasible with&#xD;
      a femoral approach, and in what amount of cases PICSO is effective to increase collateral&#xD;
      flow index (CFI). In this study an adapted collateral flow pressure index (CFpI) will be used&#xD;
      and is calculated as the ratio of the distal LAD pressure during LAD balloon occlusion&#xD;
      (PLADoccl.) and the Aortic pressure (Pao). CFI&gt;30% has been shown in several studies to be a&#xD;
      significant predictor of inducible ischemia as measured by intracoronary ST-segment changes.&#xD;
      The study is a non-randomized single centre trial using a Bayesian statistical model.&#xD;
&#xD;
      3. Specific This study is a study in 10 elective patients with coronary artery disease&#xD;
      assessing the safety and feasibility of adjunctive PICSO treatment during PCI using a femoral&#xD;
      vein approach.&#xD;
&#xD;
      Together with the preclinical experience using the Miracor technology, we therefore believe&#xD;
      that the planned cohort of 10 patients is sufficient to corroborate earlier experiences on&#xD;
      the safety of the procedure as well as present technology.&#xD;
&#xD;
      For the effectiveness, 10 sets of measurements before and after the procedure in each patient&#xD;
      will provide insight into the clinical significance since each patient will serve as her or&#xD;
      his control.&#xD;
&#xD;
      Study end-points&#xD;
&#xD;
      3.1 Primary endpoints&#xD;
&#xD;
        1. Duration from successful femoral vein cannulation until successful placement of PICSO&#xD;
           Impulse catheter into the Coronary Sinus.&#xD;
&#xD;
        2. Relative increase in collateral flow pressure index (CFpI) during LAD occlusion with and&#xD;
           without PICSO.&#xD;
&#xD;
      3.2 Secondary endpoints&#xD;
&#xD;
        1. Number of patients reaching collateral flow pressure index (CFpI) higher than 30% during&#xD;
           PICSO.&#xD;
&#xD;
        2. Quantitative evaluation of pre-condition effect on relative increase of CFpI.&#xD;
&#xD;
        3. The change of ST segment as recorded at Intra coronary ECG measures during balloon&#xD;
           inflation.&#xD;
&#xD;
      3.3 Primary safety endpoints&#xD;
&#xD;
        1. The patients are hemodynamic stable during PICSO.&#xD;
&#xD;
        2. Elevation of coronary sinus pressure&#xD;
&#xD;
        3. The 30 days MACE is comparable to other patients undergoing PCI.&#xD;
&#xD;
             1. Stroke&#xD;
&#xD;
             2. Bleeding&#xD;
&#xD;
             3. Inflammation&#xD;
&#xD;
             4. New onset of an acute coronary syndrome or newly documented heart failure,&#xD;
                requiring therapy or hospitalization&#xD;
&#xD;
             5. Pulmonary embolism&#xD;
&#xD;
             6. Coronary sinus permanent occlusion&#xD;
&#xD;
             7. Death&#xD;
&#xD;
             8. Other Adverse Events&#xD;
&#xD;
        4. No reported Adverse Events caused by PICSO&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No reported Adverse Events caused by PICSO</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The 30 days MACE is comparable to other patients undergoing PCI.</measure>
    <time_frame>30 days after intervention</time_frame>
    <description>Number of patients of reported ADE described as:&#xD;
Stroke&#xD;
Bleeding&#xD;
Inflammation&#xD;
New onset of an acute coronary syndrome or newly documented heart failure, requiring therapy or hospitalization&#xD;
Pulmonary embolism&#xD;
Coronary sinus permanent occlusion&#xD;
Death&#xD;
Other Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The patients are hemodynamic stable during PICSO.</measure>
    <time_frame>6 hours (during the whole intervention)</time_frame>
    <description>The hemodynamic is constantly monitored during the whole intervention and will be qualified by:&#xD;
Arterial pressure, LAD pressure, LAD velocity, Coronary Sinus pressure, ECG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative increase in collateral flow pressure index (CFpI) during LAD occlusion with and without PICSO.</measure>
    <time_frame>6 hours (during the whole intervention)</time_frame>
    <description>A ComboWire (VolcanoCorp, CA, USA) will be advanced in the center lumen of an occlusion balloon. This will allow performing the measurements below the experimental occlusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of ST segment as recorded at Intra coronary ECG measures during balloon inflation.</measure>
    <time_frame>6 hours (during the whole intervention)</time_frame>
    <description>The presence or absence of ECG signs of myocardial ischemia during balloon occlusion will also be assessed on-line by means of the ST segment changes &gt;0.1mV present on an intracoronary ECG lead obtained from the angioplasty guide wire placed distal to the stent (outside the OTW balloon) in the region on interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients reaching collateral flow pressure index (CFpI) higher than 30% during PICSO.</measure>
    <time_frame>6 hours (during the whole intervention)</time_frame>
    <description>A ComboWire (VolcanoCorp, CA, USA) will be advanced in the center lumen of an occlusion balloon. This will allow performing the measurements below the experimental occlusion, see also above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative evaluation of pre-condition effect on relative increase of CFpI.</measure>
    <time_frame>6 hours (during the whole intervention)</time_frame>
    <description>A ComboWire (VolcanoCorp, CA, USA) will be advanced in the center lumen of an occlusion balloon. This will allow performing the measurements below the experimental occlusion. A comparision will be made between the LAD occlusion phase with or without PICSO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration from successful femoral vein cannulation until successful placement of PICSO Impulse catheter into the Coronary Sinus.</measure>
    <time_frame>1 hours (at the begin of the intervention)</time_frame>
    <description>For each case the time will be captured and the average time will be calculated from all enrolled cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intermittent elevation of coronary sinus pressure</measure>
    <time_frame>6 hours (during the whole intervention)</time_frame>
    <description>The coronary sinus pressure will be recorded during the whole intervention. The relative mean and max. increase during the PICSO-phase will be evaluated per Patient and over all cases.</description>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Stable Angina</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PICSO</intervention_name>
    <description>Baseline (hemodynamic) measurement&#xD;
Intra coronary&#xD;
Blood sampling&#xD;
LAD occlusion: for 3 min or until pain with and without PICSO&#xD;
Break recovery: the patient can recover from pain for 3 min&#xD;
CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.&#xD;
PICSO: start automatically and continued for 10 min.&#xD;
PCI/PICSO: concomitantly for the whole duration of the PCI intervention.&#xD;
24h Follow up: additional blood samples every 6 hours (4 times)&#xD;
30 days follow up.</description>
    <other_name>PICSO Impulse System</other_name>
    <other_name>PICSO Impulse Console</other_name>
    <other_name>PICSO Impulse Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects (men or women) at least 18 years of age and&#xD;
&#xD;
          -  Coronary artery disease as assessed by angiography and&#xD;
&#xD;
          -  Clinical indication for PCI and&#xD;
&#xD;
          -  Able to understand content of and willing to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active and or treated malignancies within 12 months prior to Visit 1&#xD;
&#xD;
          -  Anatomical complications (e.g. The system in not able to effectively occlude the&#xD;
             coronary sinus)&#xD;
&#xD;
          -  Presence of significant colleteral flow supplying the target vessel (Rentrop &gt;1)&#xD;
&#xD;
          -  Any significant systemic illness or medical condition that could lead to difficulty&#xD;
             complying with the protocol; or any concurrent condition(s) which, in the&#xD;
             investigator's opinion, would prohibit the subject from completing the study, or would&#xD;
             not be in the best interest of the subject&#xD;
&#xD;
          -  Bleeding or perforation during PCI, pericardial effusion and/or hematoma&#xD;
&#xD;
          -  Cardiac arrest or arrhythmia requiring chest compressions or cardiopulmonary&#xD;
             resuscitation&#xD;
&#xD;
          -  Cardiogenic shock (Cardiac Index &lt;1.8 L/min/meter-squared or as assessed by the&#xD;
             investigator), pulmonary edema (Killip Class &gt;2), or hemodynamic instability as&#xD;
             assessed by the investigator at the time of cardiac catheterization&#xD;
&#xD;
          -  Clinically significant renal disturbance (sMDRD calculated GFRâ‰¤30 mL/min/1,73m2)&#xD;
&#xD;
          -  Coronary Sinus electrode in place&#xD;
&#xD;
          -  Acute ST elevation myocardial infarction&#xD;
&#xD;
          -  Previous Q-wave myocardial infarction in the target area&#xD;
&#xD;
          -  History of acute myocardial infarction within 72h prior to screening&#xD;
&#xD;
          -  Ejection fraction &lt;20%&#xD;
&#xD;
          -  History of stroke, any sequelae of a transient ischemic attack (TIA), reversible&#xD;
             ischemic neurological defect (RIND) within 6 months prior to screening&#xD;
&#xD;
          -  Left Bundle Branch Block&#xD;
&#xD;
          -  Mitral regurgitation (MR) &gt; grade I&#xD;
&#xD;
          -  Mitral stenosis.&#xD;
&#xD;
          -  Patient not currently in sinus rhythm&#xD;
&#xD;
          -  Patients on cardiac resynchronization therapy (CRT) or scheduled for CRT implantation&#xD;
&#xD;
          -  Patients with previous CABG or planned chronic total occlusion revascularization&#xD;
&#xD;
          -  Pregnancy or active breast-feeding. Urine pregnancy tests will be performed on all&#xD;
             women who are not post-menopausal for at least 1 year&#xD;
&#xD;
          -  Registration in another interventional study&#xD;
&#xD;
          -  Severe anemia at baseline (Hemoglobin &lt;10 g/dl or &lt;6.2 mmol/l)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan J. Piek, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>February 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <last_update_submitted>April 20, 2012</last_update_submitted>
  <last_update_submitted_qc>April 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stable Angina</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>PCI</keyword>
  <keyword>Reperfusion</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>collateral flow pressure index</keyword>
  <keyword>CFpI</keyword>
  <keyword>pressure controlled intermittent coronary sinus occlusion</keyword>
  <keyword>PICSO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

